๐
Zalmoxis
allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ฮLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
Trapianto di cellule staminali ematopoietiche; Malattia del trapianto contro l'ospite
๐ซ Ritirato
Terapia avanzata
โ
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.
A cosa serve
Zalmoxis is indicated as adjunctive treatment in haploidentical haematopoietic stem cell transplantation (HSCT) of adult patients with high-risk haematological malignancies.
โ ๏ธ Sicurezza del paziente
No
Pagina ufficiale EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/zalmoxis